Search | Clinical Trials Finder

Conditions: Kidney Transplant, Urinary Tract Infection(UTI), Antibiotic Prophylaxis, Remote Patient Monitoring, Feasibility Pilot Study
Interventions: Trimethoprim-Sulfamethoxazole (TMP-SMX), Usual Care; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Years to 29 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2033
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Afuresertib, Afuresertib/placebo; Drug
Lead sponsor: Laekna Limited; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 3 more

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Placebo, Antidepressant Therapy (ADT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 58
States / cities: Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more

Conditions: Corneal Neovascularization
Interventions: Subconjunctival aflibercept, Placebo: Standard of care only; Drug · Other
Lead sponsor: Balamurali Ambati; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cutaneous Lupus Erythematosus
Interventions: Edecesertib, Placebo, Standard of Care; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Beverly Hills, California • Clearwater, Florida • Indianapolis, Indiana + 2 more

Conditions: Uterine Atony, Uterine Atony With Hemorrhage, Cesarean Section Complications
Interventions: Calcium Chloride, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Venus Leg Ulcers
Interventions: EscharEx (EX-03), Placebo (Gel vehicle); Drug
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Opioid Use Disorder
Interventions: AZD4041, Itraconazole, Buprenorphine, Buprenorphine / Naloxone, Hydromorphone, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 2 Diabetes, End Stage Renal Disease on Dialysis
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: Chapel Hill, North Carolina • Dallas, Texas • Irving, Texas

Conditions: Venous Thromboembolism (VTE)
Interventions: Betrixaban, Enoxaparin; Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 7,513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 75
States / cities: Birmingham, Alabama • Bakersfield, California • Fresno, California + 69 more

Conditions: Anterior Cruciate Ligament Rupture
Interventions: Oxycodone, Placebo oral tablet; Drug
Lead sponsor: Emory University; Other
Eligibility: 14 Years to 40 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Atlanta, Georgia • Tucker, Georgia

Conditions: Abortion in First Trimester
Interventions: Nitrous oxide administration; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Optic Neuritis
Interventions: Efgartigimod Alfa, Placebo; Drug
Lead sponsor: Anastasia Vishnevetsky, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: COVID-19, ARDS
Interventions: SOC plus 15mg/kg EB05 IV, SOC plus Placebo IV; Biological · Other
Lead sponsor: Edesa Biotech Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Fresno, California • Fullerton, California • Coral Gables, Florida + 4 more

Conditions: Behcet Disease
Interventions: AIN457, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Baltimore, Maryland • Arlington, Texas • Houston, Texas

Conditions: Cleft Palates
Interventions: Unasyn, saline solution; Drug · Other
Lead sponsor: Joseph Losee; Other
Eligibility: 3 Months to 18 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Systemic Sclerosis-Associated PAH
Interventions: Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen; Biological · Other · Diagnostic Test + 1 more
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 17
States / cities: Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more

Conditions: Systemic Lupus Erythematosus
Interventions: Ianalumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 22
States / cities: Anniston, Alabama • Burbank, California • La Jolla, California + 19 more

Conditions: ANCA-associated Vasculitis
Interventions: CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 39
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more

Conditions: Postoperative Pain After Uterine Fibroid Embolization, Uterine Fibroids (UF), Uterine Fibroids, Pelvic Pain, Pain Management
Interventions: TUNES (Transmucosal Uterosacral Electrical Stimulation), Sham TUNES Device; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 28 Years to 52 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Systemic Lupus Erythematosus
Interventions: IFNα-Kinoid, Placebo, ISA 51 VG; Biological · Other
Lead sponsor: Neovacs; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 13
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 8 more

Conditions: Glioblastoma
Interventions: IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy, SOC: Temozolomide; Combination Product · Procedure · Drug
Lead sponsor: Imvax; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 23
States / cities: Jacksonville, Florida • Boston, Massachusetts • Detroit, Michigan + 15 more

Conditions: Congestive Heart Failure, Cardiac Transplantation, Renal Insufficiency, Renal Failure
Interventions: Natrecor (nesiritide)+Standard Care+dobutamine or milrinone, Placebo+Standard Care+dobutamine or milrinone; Drug
Lead sponsor: Scios, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 14
States / cities: Stanford, California • Tampa, Florida • Chicago, Illinois + 11 more

Conditions: Breast Cancer
Interventions: Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl); Biological · Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hickory, North Carolina

Search by objective public record fields.

Antibiotics for Kidney Transplant Recipients

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Calcium Chloride for Prevention of Uterine Atony During Cesarean

Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

DIALYSIS-TIR Study

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Are Opioids Needed After ACL Reconstruction

Nitrous Oxide for Pain Management of First Trimester Surgical Abortion

Efgartigimod for the Treatment of Acute Optic Neuritis

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19

Phase III Study in Refractory Behcet's Disease

Preventing Complications in Cleft Palate Repair With Antibiotics

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

Transmucosal Uterosacral Electrical Stimulation for Pelvic Pain Relief

Phase IIb Study of IFN-K in Systemic Lupus Erythematosus

A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC

STRIDE - STimulating Immune Response In aDvanced brEast Cancer